US2010331280A1PendingUtilityA1

Modulation of the Phospholipase A2 Pathway as a Therapeutic

68
Individually held — no corporate assignee on recordPriority: Jul 13, 1998Filed: Oct 20, 2009Published: Dec 30, 2010
Est. expiryJul 13, 2018(expired)· nominal 20-yr term from priority
Inventors:Daniel ParisTerrence TownMichael Mullan
A61K 31/366A61K 31/00A61K 31/165A61K 31/415A61K 31/685A61K 31/683A61K 31/121A61K 31/36A61K 31/4045A61P 9/00A61K 31/4439A61K 31/405A61K 31/18A61K 31/27
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is provided a method of modifying vasoactivity by regulating a soluble Aβ pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble Aβ pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble Aβ pro-inflammatory pathway is also provided. A pharmaceutical composition consisting essentially of an effective amount of a soluble Aβ pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided.

Claims

exact text as granted — not AI-modified
1 - 3 . (canceled) 
     
     
         4 . A method of treating patients with vascular disease by modifying an intracellular soluble Aβ pro-inflammatory pathway. 
     
     
         5 . The method according to  claim 4 , wherein said modifying step is further defined as blocking target molecules of the soluble Aβ pro-inflammatory pathway. 
     
     
         6 . A pharmaceutical composition comprising an effective amount of a soluble Aβ pro-inflammatory pathway regulator and a pharmaceutically effective carrier. 
     
     
         7 . The pharmaceutical composition according to  claim 6 , wherein said soluble Aβ pro-inflammatory pathway regulator blocks the activity of type I secretory PLA2. 
     
     
         8 . The pharmaceutical composition according to  claim 7 , wherein said soluble Aβ pro-inflammatory pathway regulator is a non-toxic derivative of oleyloxyethylphosphorylcholine or related compounds. 
     
     
         9 . The pharmaceutical composition according to  claim 6 , wherein said soluble Aβ pro-inflammatory pathway regulator blocks the activity of cytosolic PLA2. 
     
     
         10 . The pharmaceutical composition according to  claim 9 , wherein said soluble Aβ pro-inflammatory pathway regulator is one from the group consisting essentially of methyl arachydonyl fluorophosphonate, AACOCF 3  or related compounds. 
     
     
         11 . The pharmaceutical composition according to  claim 6 , wherein said soluble Aβ pro-inflammatory pathway regulator blocks the activity of enzymes of the LOX family. 
     
     
         12 . The pharmaceutical composition according to  claim 11  wherein said soluble Aβ pro-inflammatory pathway regulator is MK-886. 
     
     
         13 . The pharmaceutical composition according to  claim 6 , wherein said soluble A3 pro-inflammatory pathway regulator is MAP kinase inhibitor selected from the group consisting essentially of p38MAP kinase inhibitors and MEK1/2 inhibitors. 
     
     
         14 . The pharmaceutical composition according to  claim 6 , wherein said soluble Aβ pro-inflammatory pathway regulator blocks the activity of enzymes of both the LOX and COX families. 
     
     
         15 . The pharmaceutical composition according to  claim 14 , wherein said soluble Aβ pro-inflammatory pathway regulator is one from the group consisting essentially of ER-34122, BW-A4C or MK-886 in combination with non-toxic derivatives of NS-398. 
     
     
         16 . A diagnostic method including the steps of detecting modification of the soluble Aβ pro-inflammatory pathway. 
     
     
         17 . The diagnostic method according to  claim 16 , wherein said detecting step further includes detecting any up-regulation of the soluble Aβ pro-inflammatory pathway. 
     
     
         18 . The diagnostic method according to  claim 16 , wherein said detecting step further includes detecting any down-regulation of the soluble Aβ pro-inflammatory pathway. 
     
     
         19 . A method of modifying inflammatory reactions in microglia and neurons by regulating a soluble Aβ pro-inflammatory pathway. 
     
     
         20 . The method according to  claim 19 , further defined as upregulating the soluble Aβ pro-inflammatory pathway. 
     
     
         21 . The method according to  claim 19 , further defined as down-regulating the soluble Aβ pro-inflammatory pathway.

Join the waitlist — get patent alerts

Track US2010331280A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.